Dario C Altieri

List of Publications by Year
in descending order

110 papers	19,157 citations	17440 63 h-index	25787 108 g-index
110 all docs	110 docs citations	110 times ranked	15892 citing authors

#	Article	IF	Citations
1	Feasibility and safety of targeting mitochondria for cancer therapy â€“ preclinical characterization of gamitrinib, a first-in-class, mitochondriaL-targeted small molecule Hsp90 inhibitor. Cancer Biology and Therapy, 2022, 23, 117-126.	3.4	13
2	Ghost mitochondria drive metastasis through adaptive GCN2/Akt therapeutic vulnerability. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	12
3	NFÎºB activation by hypoxic small extracellular vesicles drives oncogenic reprogramming in a breast cancer microenvironment. Oncogene, 2022, 41, 2520-2525.	5.9	9
4	Wall Street Doesn't Believe in This Target. Journal of Clinical Oncology, 2022, 40, 1838-1840.	1.6	1
5	A cancer ubiquitome landscape identifies metabolic reprogramming as target of Parkin tumor suppression. Science Advances, 2021, 7, .	10.3	19
6	Protocol for assessing real-time changes in mitochondrial morphology, fission and fusion events in live cells using confocal microscopy. STAR Protocols, 2021, 2, 100767.	1.2	4
7	Small Extracellular Vesicle Regulation of Mitochondrial Dynamics Reprograms a Hypoxic Tumor Microenvironment. Developmental Cell, 2020, 55, 163-177.e6.	7.0	26
8	Interplay Between V-ATPase G1 and Small EV-miRNAs Modulates ERK1/2 Activation in GBM Stem Cells and Nonneoplastic Milieu. Molecular Cancer Research, 2020, 18, 1744-1754.	3.4	3
9	The mitophagy effector FUNDC1 controls mitochondrial reprogramming and cellular plasticity in cancer cells. Science Signaling, 2020, 13, .	3.6	51
10	Akt phosphorylation of mitochondrial Lonp1 protease enables oxidative metabolism and advanced tumor traits. Oncogene, 2019, 38, 6926-6939.	5.9	32
11	IDH2 reprograms mitochondrial dynamics in cancer through a HIFâ€1Î±â€regulated pseudohypoxic state. FASEB Journal, 2019, 33, 13398-13411.	0.5	26
12	MFF Regulation of Mitochondrial Cell Death Is a Therapeutic Target in Cancer. Cancer Research, 2019, 79, 6215-6226.	0.9	34
13	Mitochondrial fission factor is a novel Myc-dependent regulator of mitochondrial permeability in cancer. EBioMedicine, 2019, 48, 353-363.	6.1	33
14	Syntaphilin Is a Novel Biphasic Biomarker of Aggressive Prostate Cancer and a Metastasis Predictor. American Journal of Pathology, 2019, 189, 1180-1189.	3.8	4
15	Myc Regulation of a Mitochondrial Trafficking Network Mediates Tumor Cell Invasion and Metastasis. Molecular and Cellular Biology, 2019, 39, .	2.3	31
16	Myc-mediated transcriptional regulation of the mitochondrial chaperone TRAP1 controls primary and metastatic tumor growth. Journal of Biological Chemistry, 2019, 294, 10407-10414.	3.4	25
17	Survivin at a glance. Journal of Cell Science, 2019, 132, .	2.0	250
18	Mitochondrial dynamics and metastasis. Cellular and Molecular Life Sciences, 2019, 76, 827-835.	5.4	60

#	Article	IF	Citations
19	Mitochondrial HSP90 Accumulation Promotes Vascular Remodeling in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 90-103.	5.6	75
20	Syntaphilin Ubiquitination Regulates Mitochondrial Dynamics and Tumor Cell Movements. Cancer Research, 2018, 78, 4215-4228.	0.9	47
21	AML Therapy: Wake Up the Guardian and Cut Loose the Executioners. Cancer Cell, 2017, 32, 719-720.	16.8	5
22	Mitochondria on the move: emerging paradigms of organelle trafficking in tumour plasticity and metastasis. British Journal of Cancer, 2017, 117, 301-305.	6.4	49
23	Syntaphilin controls a mitochondrial rheostat for proliferation-motility decisions in cancer. Journal of Clinical Investigation, 2017, 127, 3755-3769.	8.2	37
24	Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal latency. Oncotarget, 2017, 8, 7248-7264.	1.8	42
25	A Mitochondrial-targeted purine-based HSP90 antagonist for leukemia therapy. Oncotarget, 2017, 8, 112184-112198.	1.8	17
26	Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. Journal of Clinical Investigation, 2016, 126, 1834-1856.	8.2	219
27	The Mitochondrial Unfoldase-Peptidase Complex ClpXP Controls Bioenergetics Stress and Metastasis. PLoS Biology, 2016, 14, e1002507.	5.6	118
28	A neuronal network of mitochondrial dynamics regulates metastasis. Nature Communications, 2016, 7, 13730.	12.8	112
29	Mitochondrial Akt Regulation of Hypoxic Tumor Reprogramming. Cancer Cell, 2016, 30, 257-272.	16.8	158
30	Transgenic Expression of the Mitochondrial Chaperone TNFR-associated Protein 1 (TRAP1) Accelerates Prostate Cancer Development. Journal of Biological Chemistry, 2016, 291, 25247-25254.	3.4	29
31	Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy. Clinical Cancer Research, 2016, 22, 540-545.	7.0	85
32	Survivin â€“ The inconvenient IAP. Seminars in Cell and Developmental Biology, 2015, 39, 91-96.	5.0	130
33	PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8638-8643.	7.1	174
34	Adaptive Mitochondrial Reprogramming and Resistance to PI3K Therapy. Journal of the National Cancer Institute, 2015, 107, .	6.3	91
35	Disabling mitochondrial reprogramming in cancer. Pharmacological Research, 2015, 102, 42-45.	7.1	3
36	Survivin promotes oxidative phosphorylation, subcellular mitochondrial repositioning, and tumor cell invasion. Science Signaling, 2015, 8, ra80.	3.6	84

#	Article	IF	Citations
37	Cancer cells exploit adaptive mitochondrial dynamics to increase tumor cell invasion. Cell Cycle, 2015, 14, 3242-3247.	2.6	26
38	microRNAâ€Mediated Survivin Control of Pluripotency. Journal of Cellular Physiology, 2015, 230, 63-70.	4.1	12
39	Deregulation of MiR-34b/Sox2 Predicts Prostate Cancer Progression. PLoS ONE, 2015, 10, e0130060.	2.5	23
40	Deletion of the Mitochondrial Chaperone TRAP-1ÂUncovers Global Reprogramming of Metabolic Networks. Cell Reports, 2014, 8, 671-677.	6.4	64
41	Landscape of the mitochondrial Hsp90 metabolome in tumours. Nature Communications, 2013, 4, 2139.	12.8	135
42	Targeting survivin in cancer. Cancer Letters, 2013, 332, 225-228.	7.2	156
43	Mitochondrial HSP90s and tumor cell metabolism. Autophagy, 2013, 9, 244-245.	9.1	17
44	Hsp90 regulation of mitochondrial protein folding: from organelle integrity to cellular homeostasis. Cellular and Molecular Life Sciences, 2013, 70, 2463-2472.	5.4	37
45	Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells. Journal of Clinical Investigation, 2013, 123, 2907-2920.	8.2	165
46	Chk2 Phosphorylation of Survivin-Î”Ex3 Contributes to a DNA Damageâ€“Sensing Checkpoint in Cancer. Cancer Research, 2012, 72, 3251-3259.	0.9	18
47	Control of Tumor Bioenergetics and Survival Stress Signaling by Mitochondrial HSP90s. Cancer Cell, 2012, 22, 331-344.	16.8	103
48	TRAP-1, the mitochondrial Hsp90. Biochimica Et Biophysica Acta - Molecular Cell Research, 2012, 1823, 767-773.	4.1	156
49	Aberrant Overexpression of the Cell Polarity Module Scribble in Human Cancer. American Journal of Pathology, 2011, 178, 2478-2483.	3.8	46
50	Developmental Control of Apoptosis by the Immunophilin Aryl Hydrocarbon Receptor-interacting Protein (AIP) Involves Mitochondrial Import of the Survivin Protein. Journal of Biological Chemistry, 2011, 286, 16758-16767.	3.4	35
51	Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. Journal of Clinical Investigation, 2011, 121, 1349-1360.	8.2	134
52	Essential Role of the Small GTPase Ran in Postnatal Pancreatic Islet Development. PLoS ONE, 2011, 6, e27879.	2.5	9
53	Mitochondrial Compartmentalized Protein Folding and Tumor Cell Survival. Oncotarget, 2011, 2, 347-351.	1.8	11
54	Survivin and IAP proteins in cell-death mechanisms. Biochemical Journal, 2010, 430, 199-205.	3.7	331

#	Article	IF	Citations
55	IAP Regulation of Metastasis. Cancer Cell, 2010, 17, 53-64.	16.8	258
56	Heat Shock Protein 60 Regulation of the Mitochondrial Permeability Transition Pore in Tumor Cells. Cancer Research, 2010, 70, 8988-8993.	0.9	153
57	Preclinical Characterization of Mitochondria-Targeted Small Molecule Hsp90 Inhibitors, Gamitrinibs, in Advanced Prostate Cancer. Clinical Cancer Research, 2010, 16, 4779-4788.	7.0	85
58	Dynamics-Based Discovery of Allosteric Inhibitors: Selection of New Ligands for the C-terminal Domain of Hsp90. Journal of Chemical Theory and Computation, 2010, 6, 2978-2989.	5.3	83
59	Cytoprotective Mitochondrial Chaperone TRAP-1 As a Novel Molecular Target in Localized and Metastatic Prostate Cancer. American Journal of Pathology, 2010, 176, 393-401.	3.8	113
60	Endogenous Tumor Suppression Mediated by PTEN Involves Survivin Gene Silencing. Cancer Research, 2009, 69, 4954-4958.	0.9	61
61	Survivin as a globalÂ target of intrinsic tumor suppression networks. Cell Cycle, 2009, 8, 2708-2710.	2.6	101
62	Prostate cancer regulatory networks. Journal of Cellular Biochemistry, 2009, 107, 845-852.	2.6	32
63	Survival responses of human embryonic stem cells to DNA damage. Journal of Cellular Physiology, 2009, 220, 586-592.	4.1	135
64	Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. Journal of Clinical Investigation, 2009, 119, 454-464.	8.2	198
65	Survivin, cancer networks and pathway-directed drug discovery. Nature Reviews Cancer, 2008, 8, 61-70.	28.4	903
66	Molecular Dependence of Estrogen Receptorâ€“Negative Breast Cancer on a Notch-Survivin Signaling Axis. Cancer Research, 2008, 68, 5273-5281.	0.9	111
67	Hsp60 Regulation of Tumor Cell Apoptosis. Journal of Biological Chemistry, 2008, 283, 5188-5194.	3.4	240
68	Tumor Cell Dependence on Ran-GTPâ€“Directed Mitosis. Cancer Research, 2008, 68, 1826-1833.	0.9	88
69	A Survivin-Ran Complex Regulates Spindle Formation in Tumor Cells. Molecular and Cellular Biology, 2008, 28, 5299-5311.	2.3	40
70	Regulation of Tumor Cell Mitochondrial Homeostasis by an Organelle-Specific Hsp90 Chaperone Network. Cell, 2007, 131, 257-270.	28.9	400
71	Compartmentalized Phosphorylation of IAP by Protein Kinase A Regulates Cytoprotection. Molecular Cell, 2007, 27, 17-28.	9.7	138
72	Inhibition of apoptosis by survivin improves transplantation of pancreatic islets for treatment of diabetes in mice. EMBO Reports, 2006, 7, 438-443.	4.5	31

#	Article	IF	Citations
73	The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Current Opinion in Cell Biology, 2006, 18, 609-615.	5.4	254
74	Mitosis-Independent Survivin Gene Expression In vivo and Regulation by p53. Cancer Research, 2006, 66, 3392-3395.	0.9	47
75	Survivin Modulates Microtubule Dynamics and Nucleation throughout the Cell Cycle. Molecular Biology of the Cell, 2006, 17, 1483-1493.	2.1	135
76	Regulation of Survivin Stability by the Aryl Hydrocarbon Receptor-interacting Protein. Journal of Biological Chemistry, 2006, 281, 24721-24727.	3.4	67
77	Rational design of shepherdin, a novel anticancer agent. Cancer Cell, 2005, 7, 457-468.	16.8	311
78	A Survivin Gene Signature Predicts Aggressive Tumor Behavior. Cancer Research, 2005, 65, 3531-3534.	0.9	78
79	T Cell Expansion. Immunity, 2005, 22, 534-535.	14.3	9
80	Antileukemic Activity of Shepherdin, a Novel Targeted Inhibitor of the Survivin-Hsp90 Complex.. Blood, 2005, 106, 242-242.	1.4	3
81	Acute Ablation of Survivin Uncovers p53-dependent Mitotic Checkpoint Functions and Control of Mitochondrial Apoptosis. Journal of Biological Chemistry, 2004, 279, 2077-2084.	3.4	116
82	Profiles and Legacies in Cancer Biology. Cancer Biology and Therapy, 2004, 3, 482-484.	3.4	0
83	Human Diploid Fibroblasts are Refractory to Oncogene-Mediated Transformation. Cell Cycle, 2004, 3, 255-256.	2.6	27
84	An IAP-IAP Complex Inhibits Apoptosis. Journal of Biological Chemistry, 2004, 279, 34087-34090.	3.4	332
85	Molecular circuits of apoptosis regulation and cell division control: The survivin paradigm. Journal of Cellular Biochemistry, 2004, 92, 656-663.	2.6	123
86	Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. Journal of Clinical Investigation, 2004, 114, 1117-1127.	8.2	284
87	Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. Journal of Clinical Investigation, 2004, 114, 1117-1127.	8.2	186
88	Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene, 2003, 22, 8581-8589.	5.9	832
89	Validating survivin as a cancer therapeutic target. Nature Reviews Cancer, 2003, 3, 46-54.	28.4	1,158
90	Survivin and molecular pathogenesis of colorectal cancer. Lancet, The, 2003, 362, 205-209.	13.7	308

#	Article	IF	Citations
91	Regulation of survivin function by Hsp90. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 13791-13796.	7.1	311
92	Survivin and apoptosis control. Advances in Cancer Research, 2003, 88, 31-52.	5.0	128
93	Blocking Survivin to Kill Cancer Cells. , 2003, 223, 533-542.		16
94	Survivin in apoptosis control and cell cycle regulation in cancer. Progress in Cell Cycle Research, 2003, 5, 447-52.	0.9	82
95	Full-length dominant-negative survivin for cancer immunotherapy. Clinical Cancer Research, 2003, 9, 6523-33.	7.0	78
96	A p34cdc2 survival checkpoint in cancer. Cancer Cell, 2002, 2, 43-54.	16.8	304
97	Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. Journal of Cell Science, 2002, 115, 575-585.	2.0	255
98	Regulation of microtubule stability and mitotic progression by survivin. Cancer Research, 2002, 62, 2462-7.	0.9	190
99	Interleukin-11 Up-Regulates Survivin Expression in Endothelial Cells through a Signal Transducer and Activator of Transcription-3 Pathway. Laboratory Investigation, 2001, 81, 327-334.	3.7	105
100	Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. British Journal of Haematology, 2000, 111, 196-203.	2.5	86
101	Control of Apoptosis during Angiogenesis by Survivin Expression in Endothelial Cells. American Journal of Pathology, 2000, 156, 393-398.	3.8	330
102	Expression and Targeting of the Apoptosis Inhibitor, Survivin, in Human Melanoma. Journal of Investigative Dermatology, 1999, 113, 1076-1081.	0.7	316
103	Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nature Cell Biology, 1999, 1, 461-466.	10.3	566
104	Transcriptional analysis of human survivin gene expression. Biochemical Journal, 1999, 344, 305-311.	3.7	264
105	Transcriptional analysis of human survivin gene expression. Biochemical Journal, 1999, 344, 305.	3.7	202
106	Control of apoptosis and mitotic spindle checkpoint by survivin. Nature, 1998, 396, 580-584.	27.8	1,741
107	A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Medicine, 1997, 3, 917-921.	30.7	2,939
108	Activation of Mac-1 (CD11b/CD18)-bound factor X by released cathepsin G defines an alternative pathway of leucocyte initiation of coagulation. Biochemical Journal, 1996, 319, 873-879.	3.7	82

#	Article	IF	Citations
109	Proteases and protease receptors in modulation of leukocyte effector functions. Journal of Leukocyte Biology, 1995, 58, 120-127.	3.3	46
110	Xa receptor EPRâ€1. FASEB Journal, 1995, 9, 860-865.	0.5	90